Aarti Pharmalabs Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹817

Market cap₹6.2K Cr

P/E35.0

Published11 Aug 2026

The short version

CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026. The company anticipates good growth in the CDMO business for FY '27, with budgeting and detailed guidance to be finalized by March.

From Aarti Pharmalabs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026.
Potential for substantial growth due to small base and possible 1-2 good commercial opportunities.
CDMO sales target: INR 1,000 crores; aiming for similar growth in FY '27 as FY '26.
Increasing wallet share with innovator partners; around 7-8 projects anchor 80% of CDMO sales.
New commercial molecules (from ~28 to 40) progressing to scale up revenues.
Xanthine segment planning 25-30%+ volume growth next year; with 5-10% realization improvement due to China-related dynamics.
API segment currently slow with some degrowth; expected to recover with new product launches and capacity expansion (including Atali plant).
EBITDA growth anticipated to be flat to moderate in FY '26 but with strong mid-to-long-term growth trajectory.
Expansion projects (Atali, Xanthine) to contribute progressively from FY '27 onwards.

Profitability & Margins

The company anticipates good growth in the CDMO business for FY '27, with budgeting and detailed guidance to be finalized by March.
CDMO sales target is INR 1,000 crores, with similar growth expected in FY '27 as FY '26.
EBITDA for FY '26 is expected to be largely in line with last year with marginal growth; a strong mid-to-long term growth trajectory is anticipated.
Recent margin pressures in API segment due to pricing degrowth and slow volume growth; capacity expansions and product launches are expected to aid recovery and growth.
Atali plant expansion and Xanthine plant ramp-ups projected to improve production capacity and margins progressively in FY '27.
EBITDA margins seen above 25% possible when CDMO/CMO contribution grows further.
Operational expenses from new expansions (Atali, Xanthine) may normalize once ramp-up stabilizes.
Overall, growth driven by increased wallet share in CDMO, pipeline commercializations, and capacity expansions.

See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Aarti Pharmalabs plans capital expenditure (capex) for FY27-FY28 focused on expansions: - Atali site: At least one new manufacturing block is planned for FY27 with capex approval forthcoming; described as not a large capex. - Xanthine site: Approved capex is around INR150 crores for both sites combined, with an ongoing capacity increase targeting 9,000 tonnes per annum by end of Q4. - Capex at Atali includes INR450 crores total: - INR300 crores commercialized. - INR150 crores balance remaining. - Expansion plans tied to growth visibility in CDMO business, expecting strong ramp-up post-launch of new blocks. - Debottlenecking plans for steroid and oncology blocks to enhance capacity are also underway. Overall, strategic investments focus on expanding manufacturing capacity to support growing CDMO and intermediate/API businesses.

Fundraising & Capital Structure

There are no explicit mentions of any current or future fundraising plans through debt or equity in the provided transcript.
The company discusses existing debt levels (gross debt around INR 650 crores, net debt to equity ratio expected around 0.3-0.35 post capex).
Capex projects like Atali (INR 450 crores total) and Xanthine (INR 150 crores) expansions are underway, with no direct indication of new equity or debt raising for these.
Management expects to manage capex internally, as no mention of fresh fundraises is made.
Overall, the discussion centers on operational performance, capex execution, and business growth, with no clear signals of additional fundraising plans.

See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The company has single purchase orders (POs) in the range of single-digit millions of dollars, indicating sizeable orders.
At the end of FY '25, the company had 21 CDMO customers; the number is expected to increase in calendar year 2026.
A good number of new CDMO inquiries have been generated starting this year, with hopes to win multiple RFPs.
The CDMO business pipeline includes 5-7 significant projects anchoring 80% of sales, with a dynamic list of about 60 projects being tracked.
There is a mix of customers including innovators, CDMO partners, smaller biotechs, and traders.
Some projects have wallet shares of 60-70%, indicating deep involvement in product manufacturing.
Large single-product opportunities are in the pipeline, with potential turnovers exceeding INR100-150 crores.
Bulk of CDMO shipments for newer products are expected in the last quarter, reflecting order execution scaling up.

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAarti Pharmalabs Ltd

See where Aarti Pharmalabs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

Aarti Pharmalabs Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹583 Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Aarti Pharmalabs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
Shilpa Medicare (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aarti Pharmalabs Ltd Q3 FY26 results?

What is Aarti Pharmalabs Ltd share price analysis?

Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Pharmalabs Ltd planning capital expenditure?

Aarti Pharmalabs plans capital expenditure (capex) for FY27-FY28 focused on expansions: - Atali site: At least one new manufacturing block is planned for FY27 with capex approval forthcoming; described as not a large capex.

Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.